Spotify reported first‑quarter 2026 results with total revenue of €4.533 billion, up 8% year‑over‑year on a reported basis and 14% on a constant‑currency basis, driven by strong demand in its premium subscription segment and a modest lift in ad‑supported revenue. The company’s operating income reached €715 million, a 40% increase from the €509 million reported in Q1 2025, reflecting both higher revenue and a record gross margin of 33.0%, up 133 basis points year‑over‑year. Operating margin expanded to 15.8% from 15.1% in the prior year, underscoring effective cost control and the premium‑segment mix advantage. Free cash flow hit a record €824 million, supporting the company’s shareholder return program. Premium subscribers grew to 293 million, a 9% year‑over‑year increase, while net new paid subscribers added 3 million, in line with guidance. Monthly active users reached 761 million, with the free tier maintaining robust engagement. Ad revenue fell 5% to €385 million on a reported basis but grew 3% on a constant‑currency basis, as the automated sales channel now accounts for over 30% of ad revenue. The company beat its Q1 operating‑income guidance of €660 million, but its Q2 operating‑income guidance of €630 million falls short of the analyst consensus of €684 million, signaling a more cautious near‑term outlook. Management highlighted continued investment in AI, noting that features such as “DJ” and “SongDNA” are driving engagement, and emphasized the transition to programmatic ad sales as a short‑term pressure that should yield upside later in 2026. The guidance reflects concerns about a potential slowdown in premium subscriber additions and the competitive ad‑supported market, while the strong Q1 performance demonstrates resilience and a solid foundation for future growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.